Navigation Links
Unilife COO to Again Purchase More Than $250,000 in Company Shares
Date:8/31/2011

YORK, Pa., Aug. 31, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that its Chief Operating Officer, Dr. Ramin Mojdeh, will purchase more than $250,000 in shares of the Company's common stock. This investment closely follows Dr. Mojdeh's initial open market purchase of more than $250,000 in Unilife shares in March 2011, six weeks after he joined the Company.

Dr. Mojdeh will begin making the purchase at market prices after the issuance of this release in the U.S.  This intended purchase by Dr. Mojdeh, of more than $250,000 in Unilife common stock is occurring as per the Company's insider trading policy and will be effected in compliance with applicable U.S. and Australian securities laws.

The upcoming purchase by Dr. Mojdeh follows similar activity recently undertaken by Unilife CEO Alan Shortall, as reported on August 17, 2011.  

Dr. Mojdeh stated: "Since joining Unilife nearly seven months ago, my confidence in the Company's future continues to grow. Under Mr. Shortall's guidance and keen leadership, we have been able to accomplish several important milestones including the industrialization and first sales of the Unifill syringe. Through our unparalleled capacity to identify and respond to the unmet needs of our pharmaceutical partners with speed, agility and reliability, we have developed an innovative and highly differentiated portfolio of advanced drug delivery systems.

"Unilife is very well positioned to capitalize on a paradigm shift that is now occurring within the fast-growing $10 Billion market for injectable drug delivery devices. The molecular complexity and patient-centric focus of the biologics now dominating the development pipelines of many pharmaceutical companies requires innovative device solutions that are customized to address the specific needs of each target drug. We now have the diversified portfolio, deep industry expertise and advanced operational capabilities and entrepreneurial structure to serve as a preferred partner to pharmaceutical companies seeking device innovation," concluded Dr. Mojdeh.

About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.  For more information on Unilife, please visit www.unilife.com

Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):Investor Contacts (Australia)Todd Fromer / Garth Russell

Stuart Fine

Jeff CarterKCSA Strategic Communications

Carpe DM Inc

Unilife CorporationP: + 1 212-682-6300

P: + 1 908 469 1788

P: + 61 2 8346 6500
'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011
2. Unilife Develops Proprietary Range of Auto-Injectors for Patient Self-Administration of Injectable Drugs
3. Unilife Develops Unifill® EZMix Multiple-Chamber Prefilled Syringes
4. Unilife Signs $10 Million Equipment Financing Agreement
5. Unilife Expands Management Team to Support Business Growth
6. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
7. Unilife Successfully Completes Industrialization of Unifill Syringe
8. Unilife Hosts White House Business Council Meeting
9. Unilife to Present at the 2011 Jefferies Global Healthcare Conference in New York City
10. Unilife to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London
11. Unilife Announces Financial Results for the Third Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 Eye expert s ... babies to seek an eye examination ...   Moorfields Eye Hospital Dubai, the first ... London , has identified premature babies as a special concern ... their particular vulnerability to retinopathy of prematurity (ROP). ROP is a ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two ... their patients from other participating organizations in the exchange. SJMC’s membership in the ...
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's ... advertising campaigns, to monitor the performance of sales and support staff, and to ... revenue. The software allows customers to record, transcribe, route, document, and report on ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Dr. Charles A. ... Dentistry of New Jersey in the class of 1986, where he graduated in the ... at his current location in Livingston since 1989. He has been a member in ...
Breaking Medicine News(10 mins):